← Leaderboards
Nathan Bahr
University Of Kansas Medical Center
$5,885,913
Attributed
$8,012,053
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5M · FY2019–25$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,012,053 · 4
By mechanism
R01$3,975,511 · 2
RF1$3,032,667 · 1
K23$1,003,875 · 1
Top collaborators
- David Bisagaya Meya2 shared
- Alessandro Comaru Pasqualotto2 shared
Most similar at University Of Kansas Medical Center
Same institution · by research overlap
- T. Rajendra Kumar$9,873,591
- Byron J. Gajewski$6,357,615
- Konstantine Halkidis$660,960
- Luciano Ditacchio$1,721,250
Others in their field
Other Emerging Leaders on “Mortality”
- Chanza Baytop · Westat, Inc.$271,217,917
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$56,084,949
- Greg Witham · Anp Technologies, Inc.$19,727,817
- Yunda Huang · Fred Hutchinson Cancer Center$19,033,873
- Barbara Halina Braffett · George Washington University$17,931,151
Research focus
MortalityPersonsImproved OutcomeDiagnosticDiagnostic TestsResourcesCerebrospinal FluidDiagnostic AccuracyMeningitisDiagnosisTuberculosisPredictive ValueAutopsyAfrica South Of The SaharaMycobacterialInfrastructureMeningeal TuberculosisAntigen TestEngineeringTechnologyCostGuidelinesMorbidity - Disease RateAffect
Grant awards (16)
Understanding the causes of second episode cryptococcal meningitis to improve diagnosis and treatment$1,841,519
RF1 · FY2025 · NS · contact PI
Understanding the causes of second episode cryptococcal meningitis to improve diagnosis and treatment$1,191,148
RF1 · FY2025 · NS · contact PI
Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (HISTO-FACT)$870,925
R01 · FY2025 · AI · contact PI
Determining the performance and accuracy of SILVAMP TB LAM and cost-effectiveness of diagnostic testing for TB meningitis$566,649
R01 · FY2025 · AI · contact PI
Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (HISTO-FACT)$348,689
R01 · FY2025 · AI · contact PI
Determining the performance and accuracy of SILVAMP TB LAM and cost-effectiveness of diagnostic testing for TB meningitis$146,556
R01 · FY2025 · AI · contact PI
Determining the performance and accuracy of SILVAMP TB LAM and cost-effectiveness of diagnostic testing for TB meningitis$732,368
R01 · FY2024 · AI · contact PI
Determining the performance and accuracy of SILVAMP TB LAM and cost-effectiveness of diagnostic testing for TB meningitis$360,637
R01 · FY2023 · AI · contact PI
Determining the performance and accuracy of SILVAMP TB LAM and cost-effectiveness of diagnostic testing for TB meningitis.$286,171
R01 · FY2023 · AI · contact PI
Novel Diagnostic Development for TB Meningitis and Histoplasmosis$156,066
K23 · FY2023 · NS · contact PI
Novel Diagnostic Development for TB Meningitis and Histoplasmosis$44,814
K23 · FY2023 · NS · contact PI
Determining the performance and accuracy of SILVAMP TB LAM and cost-effectiveness of diagnostic testing for TB meningitis.$663,516
R01 · FY2022 · AI · contact PI
Novel Diagnostic Development for TB Meningitis and Histoplasmosis$200,705
K23 · FY2022 · NS · contact PI
Novel Diagnostic Development for TB Meningitis and Histoplasmosis$200,705
K23 · FY2021 · NS · contact PI
Novel Diagnostic Development for TB Meningitis and Histoplasmosis$200,705
K23 · FY2020 · NS · contact PI
Novel Diagnostic Development for TB Meningitis and Histoplasmosis$200,880
K23 · FY2019 · NS · contact PI